quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2....
The goals of maintenance therapy in patients with HER2-negative metastatic breast cancer are to improve and maintain clinical response, increase time to progression, extend overall survival, relieve tumor-related symptoms, and delay the use of aggressive therapies, without compromising quality of life....
[1] Bardia A, Rugo HS, Tolaney SM, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor...
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Lancet Oncol, 24 (1) (2023), pp. 77-90 View PDFView articleView in...
(HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogenreceptor /progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used ...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
Triple negative breast cancer (TNBC) means that the cancer cells do not have estrogen (ER) and progesterone (PR) on their surface, and they do not over-express the HER2 protein as well (HER2−). In contrast to TNBC, triple positive breast cancer means the cancer cells are ER+, PR+,...
In the first of these, 140 patients with HER2-overexpressing and 89 with HER2 negative advanced breast cancer were treated with lapatinib 1500 mg daily.59 This was a heavily pre- treated population, 76% of patients having received 4 or more lines of prior chemotherapy. There were no responses...
1)要係侵蝕性癌(invasive cancer)。原位癌係冇分HER2唔HER2型嘅。 2)HER2陽性(HER2+):一係cerbB2 score 3,一係cerbB2 score2 +FISH positive。 伸延閲讀:乳癌類型巡禮 - 與你細數HER2型乳癌的歴史 「我係HER2型呀,請講落去⋯⋯」 乳癌標靶藥Herceptin ...
I think one of the nice things about these ongoing studies is that they do separate out the subtypes, because I think the answer to the surveillance question may be different in patients with HER2-positive disease vs those with triple-negative breast cancer, where post–brain metastases survival...